GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spago Nanomedical AB (XSAT:SPAG BTA) » Definitions » Gross-Profit-to-Asset %

Spago Nanomedical AB (XSAT:SPAG BTA) Gross-Profit-to-Asset % : -28.38% (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Spago Nanomedical AB Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Spago Nanomedical AB's annualized Gross Profit for the quarter that ended in Mar. 2025 was kr-9.92 Mil. Spago Nanomedical AB's average Total Assets over the quarter that ended in Mar. 2025 was kr34.94 Mil. Therefore, Spago Nanomedical AB's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was -28.38%.


Spago Nanomedical AB Gross-Profit-to-Asset % Historical Data

The historical data trend for Spago Nanomedical AB's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spago Nanomedical AB Gross-Profit-to-Asset % Chart

Spago Nanomedical AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.27 -9.47 -7.85 -17.98 -26.70

Spago Nanomedical AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.97 -24.95 -29.72 -23.58 -28.38

Competitive Comparison of Spago Nanomedical AB's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Spago Nanomedical AB's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spago Nanomedical AB's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spago Nanomedical AB's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Spago Nanomedical AB's Gross-Profit-to-Asset % falls into.


;
;

Spago Nanomedical AB Gross-Profit-to-Asset % Calculation

Spago Nanomedical AB's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=-12.358/( (52.985+39.583)/ 2 )
=-12.358/46.284
=-26.70 %

Spago Nanomedical AB's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=-9.916/( (39.583+30.288)/ 2 )
=-9.916/34.9355
=-28.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Spago Nanomedical AB Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Spago Nanomedical AB's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Spago Nanomedical AB Business Description

Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, SE-223 63
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.

Spago Nanomedical AB Headlines

No Headlines